Back to News
Market Impact: 0.35
Apnimed shares surge on bullish BofA initiation
Source: proactiveinvestors.com
Analyst InsightsAnalyst EstimatesCompany FundamentalsTechnology & Innovation
Apnimed shares rose 8% Tuesday after BofA Securities initiated coverage with a Buy rating and a $41 price target. The view is grounded in a risk-adjusted discounted cash flow model centered on Oxnimbi (AD109), Apnimed’s sole asset, an oral therapy for obstructive sleep apnea (OSA).
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
APMD0.55
More News
- Soitec climbs 7% as BofA turns bullish on silicon photonics demand
- ‘The gap was not the awareness’: The company phishing trainings you loathe aren’t enough when nearly 1 in 4 security pros say their MFA is optional
- Is AI the new China Shock?
- Why is T-Mobile stock tumbling today?
- This exchange stock is a buy on renewed options deal, Morgan Stanley says
- India calls JD Vance's comments about immigrants 'deeply offensive'